In a previous article I have discussed Why eSource? The answer is clear. The demand for real time data in clinical trials continues to grow because of the need for faster access to safety signals, faster access to decision making data, such as patient eligibility and dose escalation, faster access to efficacy data. And what does this speed ultimately provide? Not only can the industry get lifesaving products to the patient sooner, money can be saved during the process.
We are currently living in a world where medicine has an answer for just about everything, these answers have meant that we live far beyond what might be our ‘natural’ life expectancy. As anyone who has watched a bit of sci-fi will know, races or beings that replicate by cloning often die out, because making copies of copies of copies leads to degradation of information. The cells in our bodies replicate by copying - division, we make new from old and do pretty well at it for a long time (bar any bad genetics getting in the way).
An Obstructed View of Clinical Data? Looking Back at DIA 2017
30 Jun 2017
This photo, taken from a Wrigley Rooftop at a hosted DIA 2017 event, made me think, “What an interesting analogy for clinical trials… an obstructed view.” (Disclaimer: Before I go on, I must point out that my colleague and I had a lovely time at this event and we are very grateful to our hosts!)
The comparison begins with our gracious hosts who, up until the day of the event, expected they’d have a complete view of the game.